HC Wainwright & Co. Downgrades Innate Pharma to Neutral

Benzinga Newsdesk Sep 18, 2025 1 year ago

NewsDowngradesAnalyst Ratings

HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Innate Pharma (NASDAQ:IPHA) from Buy to Neutral.